This suggests Annexin A2 has an integral role in the degradation of fibronectin by cancer cells and modulating Annexin A2 activity could be a viable therapeutic strategy, in the yet unsuccessful targeting of plasmin-mediated cancer cell dissemination (102, 103). This evidence concerns the gene FN1 and cancer.